Page 2 - மெத்தே க்ரூஸ் டேனியல்சன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Resolutions from the Annual General Meeting of Novo Nordisk A/S
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Correction: Resolutions from the Annual General Meeting of Novo Nordisk A/S
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Adults with obesity treated with semaglutide 2 4 mg achieved and maintained a significant amount of weight loss in a 68-
europapress.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europapress.es Daily Mail and Mail on Sunday newspapers.
Novo Nordisk s net profit increased by 8% in 2020 Novo Nordisk A/S
Financial report for the period 1 January 2020 to 31 December 2020
Sales increased by 4% in Danish kroner and by 7% at CER to DKK 126.9 billion. Sales in International Operations increased by 7% in Danish kroner (10% at CER), and sales in North America Operations increased by 1% in Danish kroner (3% at CER). Sales growth was negatively impacted by COVID-19, driven by fewer patients initiating treatment.
Sales within Diabetes and Obesity care increased by 5% to DKK 108.0 billion (8% at CER), driven by GLP-1 growth of 26% in Danish kroner (29% at CER) reflecting the uptake of Ozempic
® and Rybelsus
®. Biopharm sales decreased by 1% in Danish kroner (increased by 1% at CER).
(2)
Bagsværd, Denmark, 16 December 2020 - Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities.
Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 3,700 people with early Alzheimer s disease. The programme is planned for initiation in the first half of 2021 and will investigate the efficacy and safety of once-daily oral semaglutide, compared to placebo. The expected main treatment period in the trials is around two years.